142 related articles for article (PubMed ID: 21206334)
1. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection.
Ji F; Li Z; Xue H; Liu L; Deng H
South Med J; 2011 Feb; 104(2):140-2. PubMed ID: 21206334
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon induced interstitial pneumonitis in a patient with hepatitis C infection.
Torres-Macho J; Jara-Chinarro B; Suárez-Aliaga B; Gámez-Díez S; García-de-Casasola G; de-Cuenca-Morón B
Rev Esp Enferm Dig; 2010 Oct; 102(10):606-8. PubMed ID: 21039072
[TBL] [Abstract][Full Text] [Related]
3. Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.
Arora A; Vargas L; Kuzniar TJ
J Hosp Med; 2009 Sep; 4(7):E45-6. PubMed ID: 19753589
[TBL] [Abstract][Full Text] [Related]
4. Interstitial pneumonitis after treatment for hepatitis C virus infection.
Botnaru V; Munteanu O; Rusu D
Pneumologia; 2015; 64(1):46-50. PubMed ID: 26016056
[TBL] [Abstract][Full Text] [Related]
5. A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
Shimada M; Yoshida S; Kornek M; Kim SJ; Schuppan D
Liver Int; 2010 Nov; 30(10):1552-4. PubMed ID: 20557455
[No Abstract] [Full Text] [Related]
6. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
Fuhrmann V; Kramer L; Bauer E; Laferl H; Tucek G; Dekan G; Schenk P
Dig Dis Sci; 2004; 49(11-12):1966-70. PubMed ID: 15628735
[No Abstract] [Full Text] [Related]
7. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.
Abi-Nassif S; Mark EJ; Fogel RB; Hallisey RK
Chest; 2003 Jul; 124(1):406-10. PubMed ID: 12853555
[TBL] [Abstract][Full Text] [Related]
8. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.
Carrillo-Esper R; González-Avila D; Uribe-Ríos M; Méndez-Sánchez N
Ann Hepatol; 2008; 7(1):87-90. PubMed ID: 18376374
[TBL] [Abstract][Full Text] [Related]
9. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
[TBL] [Abstract][Full Text] [Related]
10. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
[TBL] [Abstract][Full Text] [Related]
11. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Chen YC; Lu SN; Lin MC
Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
13. [Pericardial effusion associated to interferon in an immunocompetent patient].
Velasco J; Oriñuela I; Sanjuán AZ; Ortiz de Zárate Z
Enferm Infecc Microbiol Clin; 2010 Dec; 28(10):749-50. PubMed ID: 20579776
[No Abstract] [Full Text] [Related]
14. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
Farshidi D; Chiu MW
J Am Acad Dermatol; 2010 Jan; 62(1):164-165. PubMed ID: 20082904
[No Abstract] [Full Text] [Related]
15. Peripheral nervous system involvement in a haemodialysis patient treated with pegylated interferon.
Ruiz-Fuentes MC; Rubert-Gómez De Quero A; De Gracia-Guindo C; Galindo-Sacristán P; Osuna-Ortega A
Nefrologia; 2012; 32(6):863-5. PubMed ID: 23169385
[No Abstract] [Full Text] [Related]
16. [Induced interstitial pneumonitis: role of pegylated interferon alpha 2b].
Rocca P; Dumortier J; Tanière P; Duperret S; Vial T; Cottin V; Delafosse B; Scoazec JY; Boillot O
Gastroenterol Clin Biol; 2002 Apr; 26(4):405-8. PubMed ID: 12070414
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M
Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205
[No Abstract] [Full Text] [Related]
18. Interstitial pneumonia recurrence during chronic hepatitis C treatment.
Renou C; Germain S; Harafa A; Martin S; Larroque O; Muller P; Bertrand JJ; Halfon P
Am J Gastroenterol; 2005 Jul; 100(7):1625-6. PubMed ID: 15984999
[No Abstract] [Full Text] [Related]
19. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
20. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
